表紙
市場調查報告書

接觸性皮膚炎(CD)-流行病學預測:2030年

Contact Dermatitis (CD) - Epidemiology Forecast-2030

出版商 DelveInsight Business Research LLP 商品編碼 948134
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
接觸性皮膚炎(CD)-流行病學預測:2030年 Contact Dermatitis (CD) - Epidemiology Forecast-2030
出版日期: 2020年07月01日內容資訊: 英文 100 Pages
簡介

2017年,七個主要國家/地區的被診斷患有接觸性皮膚炎(CD)的人數為43,359,201。在美國,是13,786,942。在五個歐洲國家中,德國最大,為6,645,210,其次是法國,為5,481,080。最低的是西班牙,為1,982,709。在日本,是5,107,575。

該報告調查並分析了接觸性皮膚炎(CD),並概述了該疾病,診斷指南,流行病學,美國/歐洲5個國家(德國,西班牙,意大利,法國,英國)以及日本患者的考慮因素。提供有關的系統信息。

內容

第1章主要注意事項

第2章接觸性皮膚炎(CD)概述

第3章接觸性皮膚炎(CD)執行摘要

第4章疾病的背景和概述:接觸性皮膚炎(CD)

  • 類型
    • 刺激性接觸性皮膚炎(ICD)
    • 過敏性接觸性皮膚炎(ACD)
    • 聯繫蕁麻疹
  • 原因
    • 金屬
    • 香味
    • 抗菌藥膏
    • 甲醛
    • 異塞唑林酮
    • 椰油□胺基丙基甜菜鹼
    • 對苯二胺
  • 症狀
  • 病理生理學
  • 診斷

第5章CD診斷/管理算法

第6章美國過敏,哮喘和免疫學學會(AAAAI)診斷指南

  • 臨床評估
  • 補丁測試建議
  • 暴露於臨床相關過敏原的來源
  • 外用CD
  • 特定年齡段
    • 兒科CD
    • 職業CD

第7章英國皮膚科醫生協會(BAD)診斷指南

  • 評估和調查
  • 診斷測試(診斷)
    • 準備病人
    • 補丁測試
    • 補丁測試測量時間
    • 積極的反應讀物和相關性
    • 照片補丁測試
    • 開放補丁測試

第8章流行病學和患者人群:主要發現

  • 七個主要國家/地區患有CD的總人數

第9章按國家劃分的接觸性皮炎(CD)流行病學

  • 美國
  • 五個歐洲國家
  • 德國
  • 法國
  • 意大利
  • 西班牙
  • 英國
  • 日本

第10章附錄

第11章DelveInsight服務內容

第12章免責聲明

第13章關於Delve Insight

目錄
Product Code: DIEI0546

DelveInsight's 'Contact Dermatitis (CD) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted Contact Dermatitis (CD) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Dermatitis (CD) Understanding

Contact dermatitis (CD) is a type of eczema triggered by contact with a particular substance in the environment that the person is allergic to, it may react by causing the skin to itch and become red. Eczema is the name for a group of conditions that cause skin to become dry and irritated. CD usually improves or clears up completely if the substance causing the problem is identified and avoided. Treatments are also available to help ease the symptoms.

CD is a common inflammatory skin condition characterized by erythematous and pruritic skin lesions that occur after contact with a foreign substance. The most common substances that cause CD include poison ivy, nickel, and fragrances. CD usually leads to erythema and scaling with visible borders. Itching and discomfort may also occur.

Clinical symptoms depend primarily on whether the dermatitis is acute or chronic, as well as on the toxin involved, type of contact, pathomechanism, and localization, among other factors. Although all types of dermatitis generally share common features, the classic eczematous stages in CD are most readily identifiable.

Acute CD is characterized by pathological symptoms over the entire lesion:

  • Mild form: erythema at the site of exposure to the toxin, contact traces, and itching are possible.
  • Severe form: ranging from vesicular papules to blisters, usually causing strong itching. A feeling of tightness of the skin and even pain may occur. Blister rupture is followed by weeping, scab formation, and later by scaliness. Spreading reactions are possible in the case of an allergic trigger.

CD is a common skin problem occurring in 15-20% of people. Irritant Contact Dermatitis (ICD) is more common (80%) and can occur in anyone, especially after repeated exposure. Allergic contact dermatitis (ACD), on the other hand, is seen in genetically predisposed and previously sensitized individuals who react to even low concentrations of the agent. Cosmetics, medicines, clothes dyes, as well as foods, rubber and poison ivy are common causes of ACD. Any topical cream or ointment may contain chemicals that irritate the skin.

Contact Dermatitis (CD) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of Contact Dermatitis, Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution, Gender-specific Diagnosed Prevalent Population of Contact Dermatitis, Age-specific Diagnosed Prevalent Population of Contact Dermatitis and Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Contact Dermatitis (CD) Detailed Epidemiology Segmentation

  • The total diagnosed prevalent population of CD in the 7 major markets was found to be 43,359,201 in 2017.
  • In case of CD in the United States, the diagnosed prevalent cases were found to be 13,786,942 in 2017.
  • It was found that in the United States the number of cases of ICD and ACD were 11,029,554 and 2,757,388 respectively in 2017.
  • In addition, the number of cases of acute, sub-acute and chronic type of CD were 7,611,771, 2,903,530 and 3,271,641 respectively in 2017, in the United States.
  • Gender-specific data of the United States suggests that the number of cases of CD in males and females were 4,825,430 and 8,961,513 respectively in 2017.
  • Age-specific data for CD suggests that in the United States the maximum number of cases of CD were found in the age group of 46-60 with 4,411,822 cases in 2017, while the lowest number of cases were found in the age group 75+ with 275,739 cases in 2017.
  • In the EU5 countries, the diagnosed prevalence of CD was found to be maximum in Germany with 6,645,210 cases, followed by France with 5,481,080 cases in 2017. While, the least number of cases were found in Spain, with 1,982,709 cases in 2017.
  • In Japan, the diagnosed prevalence of CD was found to be 5,107,575 in 2017.

Scope of the Report:

  • The report covers the descriptive overview of Contact Dermatitis (CD), explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Contact Dermatitis (CD).
  • The report provides the segmentation of the disease epidemiology for the 7MM by Total Diagnosed Prevalent Population of Contact Dermatitis (CD) and Severity-based Diagnosed Prevalent Population of Contact Dermatitis (CD).

Report Highlights:

  • Eleven Year Forecast of Contact Dermatitis (CD)
  • 7MM Coverage
  • Total Diagnosed Prevalent Population of Contact Dermatitis (CD)
  • DelveInsight has analyzed type-based data for Contact Dermatitis (CD). Contact Dermatitis can be of two types based on this data, namely, Irritant Contact Dermatitis (ICD) and Allergic Contact Dermatitis (ACD).
  • Type-specific data based on clinical and biological evolution of Contact Dermatitis (CD) has also been analyzed by Delvelnsight. On this basis, Contact Dermatitis can be divided as Acute, Sub-acute and Chronic type.
  • In addition, Delvelnsight has also analyzed gender-specific data for Contact Dermatitis (CD), which clearly suggests that CD is more prevalent among females than males.
  • The report also encompasses another major segment, i.e., Age-specific Diagnosed Prevalent Population of Contact Dermatitis (CD), wherein various age groups have been considered, such as 0-17, 18-29, 30-45, 46-60, 61-75 and 75+. It has been found that CD majorly affects patients whose age is 40 years or above.
  • Expected Launch of a potential therapy, EB01 (Edesa Biotech), may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of Contact Dermatitis (CD).
  • The current treatment of Contact Dermatitis (CD) is mainly dominated by the use of off-label therapies, which includes Topical Corticosteroids (Clobetasol and Triamcinolone) and Emollients, Topical Immunosupressants (Pimecromilus and Tacrolimus), Systemic Immunosupressants (Antihistamines) and Corticosteroids and Others (Antiseptics, Topical Antibiotics, Phototherapy and Other Immunosupressants).

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Contact Dermatitis (CD)?
  • What is the historical Contact Dermatitis (CD) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Contact Dermatitis (CD) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Contact Dermatitis (CD)?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Contact Dermatitis (CD) during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Reasons to buy:

The Contact Dermatitis (CD) report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Contact Dermatitis (CD) market.
  • Quantify patient share distribution in the 7MM for Contact Dermatitis (CD).
  • The Contact Dermatitis (CD) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Contact Dermatitis (CD) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents

1 Key Insights

2 Contact Dermatitis Overview at a Glance

3 Executive Summary of Contact Dermatitis (CD)

4 Disease Background and Overview: Contact Dermatitis (CD)

  • 4.1 Types
    • 4.1.1 Irritant Contact Dermatitis (ICD)
    • 4.1.2 Allergic Contact Dermatitis (ACD)
    • 4.1.3 Contact Urticaria
  • 4.2 Causes
    • 4.2.1 Metals
    • 4.2.2 Fragrances
    • 4.2.3 Antibacterial Ointments
    • 4.2.4 Formaldehyde
    • 4.2.5 Isothiazolinones
    • 4.2.6 Cocamidopropyl Betaine
    • 4.2.7 Paraphenylene-Diamine
  • 4.3 Symptoms
  • 4.4 Pathophysiology
  • 4.5 Diagnosis

5 Algorithm for Diagnosis and Management of CD

6 Diagnostic Guidelines by American Academy of Allergy Asthma & Immunology (AAAAI)

  • 6.1 Clinical Evaluation
  • 6.2 Patch testing recommendations
  • 6.3 Sources of exposure to clinically relevant allergens
  • 6.4 Topical medicinal CD
  • 6.5 Special populations
    • 6.5.1 CD in children
    • 6.5.2 Occupational CD

7 Diagnostic Guidelines by the British Association of Dermatologists (BAD)

  • 7.1 Assessment and Investigation
  • 7.2 Diagnostic Tests (Diagnosis)
    • 7.2.1 Preparation of the patient
    • 7.2.2 Patch testing
    • 7.2.3 Timing of patch test readings
    • 7.2.4 Reading and relevance of positive reactions
    • 7.2.5 Photopatch testing
    • 7.2.6 Open patch testing

8 Epidemiology and Patient Population: Key Findings

  • 8.1 7MM 7MM Total Diagnosed Prevalent Population of Contact Dermatitis

9 Country Wise-Epidemiology of Contact Dermatitis

  • 9.1 United States
    • 9.1.1 Assumptions and Rationale
    • 9.1.2 Total Diagnosed Prevalent Population of Contact Dermatitis in the United States
    • 9.1.3 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in the United States
    • 9.1.4 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States
    • 9.1.5 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States
    • 9.1.6 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States
  • 9.2 EU5 Countries
    • 9.2.1 Assumptions and Rationale
  • 9.3 Germany
    • 9.3.1 Total Diagnosed Prevalent Population of Contact Dermatitis in Germany
    • 9.3.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Germany
    • 9.3.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany
    • 9.3.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany
    • 9.3.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany
  • 9.4 France
    • 9.4.1 Total Diagnosed Prevalent Population of Contact Dermatitis in France
    • 9.4.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in France
    • 9.4.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in France
    • 9.4.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in France
    • 9.4.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in France
  • 9.5 Italy
    • 9.5.1 Total Diagnosed Prevalent Population of Contact Dermatitis in Italy
    • 9.5.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Italy
    • 9.5.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy
    • 9.5.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy
    • 9.5.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy
  • 9.6 Spain
    • 9.6.1 Total Diagnosed Prevalent Population of Contact Dermatitis in Spain
    • 9.6.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Spain
    • 9.6.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain
    • 9.6.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain
    • 9.6.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain
  • 9.7 United Kingdom
    • 9.7.1 Total Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom
    • 9.7.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in the United Kingdom
    • 9.7.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom
    • 9.7.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom
    • 9.7.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom
  • 9.8 Japan
    • 9.8.1 Assumptions and Rationale
    • 9.8.2 Total Diagnosed Prevalent Population of Contact Dermatitis in Japan
    • 9.8.3 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Japan

10 Appendix

  • 10.1 Bibliography
  • 10.2 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight

List of Tables

  • Table 1: Summary of Contact Dermatitis, Market, Epidemiology and Key Events (2017-2030)
  • Table 2: Classical clinical forms of CD
  • Table 3: Features that distinguishes between Irritant and Allergic Contact Dermatitis
  • Table 4: Exogenous and endogenous factors affecting clinical characteristics of CD
  • Table 5: The most important non-eczematous symptoms of contact allergic reactions
  • Table 6: Differential Diagnosis of Contact Dermatitis
  • Table 7: Scoring of patch test reactions according to the International Contact Dermatitis Research Group recommendations
  • Table 8: Total Diagnosed Prevalent Population of Contact Dermatitis in the 7MM (2017-2030)
  • Table 9: Total Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017-2030)
  • Table 10: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in the US (2017-2030)
  • Table 11: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017-2030)
  • Table 12: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017-2030)
  • Table 13: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017-2030)
  • Table 14: Total Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017-2030)
  • Table 15: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in Germany (2017-2030)
  • Table 16: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017-2030)
  • Table 17: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017-2030)
  • Table 18: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017-2030)
  • Table 19: Total Diagnosed Prevalent Population of Contact Dermatitis in France (2017-2030)
  • Table 20: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in France (2017-2030)
  • Table 21: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in France (2017-2030)
  • Table 22: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in France (2017-2030)
  • Table 23: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in France (2017-2030)
  • Table 24: Total Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017-2030)
  • Table 25: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in Italy (2017-2030)
  • Table 26: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017-2030)
  • Table 27: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017-2030)
  • Table 28: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017-2030)
  • Table 29: Total Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017-2030)
  • Table 30: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in Spain (2017-2030)
  • Table 31: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017-2030)
  • Table 32: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017-2030)
  • Table 33: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017-2030)
  • Table 34: Total Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017-2030)
  • Table 35: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in the UK (2017-2030)
  • Table 36: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017-2030)
  • Table 37: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017-2030)
  • Table 38: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017-2030)
  • Table 39: Total Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017-2030)
  • Table 40: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in Japan (2017-2030)
  • Table 41: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017-2030)
  • Table 42: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017-2030)
  • Table 43: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017-2030)

List of Figures

  • Figure 1: Pathophysiology of Allergic and Irritant CD
  • Figure 2: Algorithm for Diagnosis and Management of CD
  • Figure 3: Total Diagnosed Prevalent Population of Contact Dermatitis in the 7MM (2017-2030)
  • Figure 4: Total Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017-2030)
  • Figure 5: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in the United States (2017-2030)
  • Figure 6: Gender-specific Diagnosed Prevalent Population of CD in the United States (2017-2030)
  • Figure 7: Age-specific Diagnosed Prevalent Population of CD in the United States (2017-2030)
  • Figure 8: Type-specific Diagnosed Prevalent Population of CD in the United States (2017-2030)
  • Figure 9: Total Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017-2030)
  • Figure 10: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Germany (2017-2030)
  • Figure 11: Gender-specific Diagnosed Prevalent Population of CD in Germany (2017-2030)
  • Figure 12: Age-specific Diagnosed Prevalent Population of CD in Germany (2017-2030)
  • Figure 13: Type-specific Diagnosed Prevalent Population of CD in Germany (2017-2030)
  • Figure 14: Total Diagnosed Prevalent Population of Contact Dermatitis in France (2017-2030)
  • Figure 15: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in France (2017-2030)
  • Figure 16: Gender-specific Diagnosed Prevalent Population of CD in France (2017-2030)
  • Figure 17: Age-specific Diagnosed Prevalent Population of CD in France (2017-2030)
  • Figure 18: Type-specific Diagnosed Prevalent Population of CD in France (2017-2030)
  • Figure 19: Total Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017-2030)
  • Figure 20: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Italy (2017-2030)
  • Figure 21: Gender-specific Diagnosed Prevalent Population of CD in Italy (2017-2030)
  • Figure 22: Age-specific Diagnosed Prevalent Population of CD in Italy (2017-2030)
  • Figure 23: Type-specific Diagnosed Prevalent Population of CD in Italy (2017-2030)
  • Figure 24: Total Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017-2030)
  • Figure 25: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Spain (2017-2030)
  • Figure 26: Gender-specific Diagnosed Prevalent Population of CD in Spain (2017-2030)
  • Figure 27: Age-specific Diagnosed Prevalent Population of CD in Spain (2017-2030)
  • Figure 28: Type-specific Diagnosed Prevalent Population of CD in Spain (2017-2030)
  • Figure 29: Total Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017-2030)
  • Figure 30: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in the United Kingdom (2017-2030)
  • Figure 31: Gender-specific Diagnosed Prevalent Population of CD in the United Kingdom (2017-2030)
  • Figure 32: Age-specific Diagnosed Prevalent Population of CD in the United Kingdom (2017-2030)
  • Figure 33: Type-specific Diagnosed Prevalent Population of CD in the United Kingdom (2017-2030)
  • Figure 34: Total Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017-2030)
  • Figure 35: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Japan (2017-2030)
  • Figure 36: Gender-specific Diagnosed Prevalent Population of CD in Japan (2017-2030)
  • Figure 37: Age-specific Diagnosed Prevalent Population of CD in Japan (2017-2030)
  • Figure 38: Type-specific Diagnosed Prevalent Population of CD in Japan (2017-2030)